6.
Caramalho R, Maurer E, Binder U, Araujo R, Dolatabadi S, Lass-Florl C
. Etest cannot be recommended for in vitro susceptibility testing of mucorales. Antimicrob Agents Chemother. 2015; 59(6):3663-5.
PMC: 4432123.
DOI: 10.1128/AAC.00004-15.
View
7.
Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P
. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015; 59(3):1745-50.
PMC: 4325796.
DOI: 10.1128/AAC.04435-14.
View
8.
Gomes M, Lewis R, Kontoyiannis D
. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011; 24(2):411-45.
PMC: 3122490.
DOI: 10.1128/CMR.00056-10.
View
9.
Boelaert J, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A
. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993; 91(5):1979-86.
PMC: 288195.
DOI: 10.1172/JCI116419.
View
10.
Roden M, Zaoutis T, Buchanan W, Knudsen T, Sarkisova T, Schaufele R
. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5):634-53.
DOI: 10.1086/432579.
View
11.
Kwon-Chung K
. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012; 54 Suppl 1:S8-S15.
PMC: 3276235.
DOI: 10.1093/cid/cir864.
View
12.
Spellberg B, Edwards Jr J, Ibrahim A
. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005; 18(3):556-69.
PMC: 1195964.
DOI: 10.1128/CMR.18.3.556-569.2005.
View
13.
Ibrahim A, Gebermariam T, Fu Y, Lin L, Husseiny M, French S
. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007; 117(9):2649-57.
PMC: 1957543.
DOI: 10.1172/JCI32338.
View
14.
Cornely O, Arikan-Akdagli S, Dannaoui E, Groll A, Lagrou K, Chakrabarti A
. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014; 20 Suppl 3:5-26.
DOI: 10.1111/1469-0691.12371.
View
15.
Van Cutsem J, Boelaert J
. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 1989; 36(6):1061-8.
DOI: 10.1038/ki.1989.301.
View
16.
Walther G, Pawlowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela J, Dolatabadi S
. DNA barcoding in Mucorales: an inventory of biodiversity. Persoonia. 2013; 30:11-47.
PMC: 3734965.
DOI: 10.3767/003158513X665070.
View
17.
Chamilos G, Lewis R, Kontoyiannis D
. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008; 47(4):503-9.
DOI: 10.1086/590004.
View